Click Therapeutics, a mental-health-focused digital therapeutics provider, has acquired the assets of cardiometabolic digital therapeutic provider Better Therapeutics for an undisclosed sum. The assets acquired include Better Therapeutics' FDA-authorized prescription digital therapeutic for type 2 diabetes (AspyreRx - BT-001) and other assets related to the treatment of obesity, hypertension, and hyperlipidemia.
With the acquisition of Better Therapeutics' assets, Click Therapeutics plans to bolster its development efforts in obesity and cardiometabolic diseases. It aims to fuse AspyreRx's clinically validated digital behavioral therapy with Click's AI-enabled platform to enhance patient care and provider capabilities. Click Therapeutics believes that its drug-software combination products can elevate patient care, improve clinical outcomes, and deliver valuable real-world data insights for providers and payers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.